Clinical Trial

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Study acronym: CanTreatCOVID
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-11-09; most recent amendment 2025-05-13.
Status change: Recruiting → Active, Not Recruiting 2025-05-13
Status change: Not Yet Recruiting → Recruiting 2023-02-08
Trial Details
NCT Number NCT05614349
Lead Sponsor Unity Health Toronto
Collaborators: Health Canada, Canadian Institutes of Health Research (CIHR)
Conditions COVID-19
Enrollment 797 participants
Start Date 2023-01-16
Primary Completion 2025-04-28 (estimated)
Study Completion 2025-06-28 (estimated)
Updated on ClinicalTrials.gov 2025-05-16